Wuhan Hvsen Biotechnology Co Ltd Asset Resilience Ratio
Wuhan Hvsen Biotechnology Co Ltd asset resilience ratio. Wuhan Hvsen Biotechnology Co Ltd (300871) has an Asset Resilience Ratio of 6.29% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Wuhan Hvsen Biotechnology Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Wuhan Hvsen Biotechnology Co Ltd (2020–2025)
Asset resilience ratio of Wuhan Hvsen Biotechnology Co Ltd from 2020 to 2025. This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read Wuhan Hvsen Biotechnology Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Wuhan Hvsen Biotechnology Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥214.41 Million | 6.29% |
| Total Liquid Assets | CN¥214.41 Million | 6.29% |
Asset Resilience Insights
- Limited Liquidity: Wuhan Hvsen Biotechnology Co Ltd maintains only 6.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Hvsen Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Wuhan Hvsen Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Wuhan Hvsen Biotechnology Co Ltd Asset Resilience Ratio by Year (2020–2025)
Wuhan Hvsen Biotechnology Co Ltd asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Wuhan Hvsen Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.33% | CN¥160.33 Million ≈ $23.46 Million |
CN¥3.01 Billion ≈ $440.25 Million |
-1.34pp |
| 2024-12-31 | 6.67% | CN¥200.97 Million ≈ $29.41 Million |
CN¥3.01 Billion ≈ $441.14 Million |
-3.56pp |
| 2023-12-31 | 10.23% | CN¥304.26 Million ≈ $44.52 Million |
CN¥2.98 Billion ≈ $435.40 Million |
-1.87pp |
| 2022-12-31 | 12.10% | CN¥361.68 Million ≈ $52.92 Million |
CN¥2.99 Billion ≈ $437.40 Million |
+11.00pp |
| 2021-12-31 | 1.10% | CN¥30.22 Million ≈ $4.42 Million |
CN¥2.74 Billion ≈ $401.19 Million |
-12.63pp |
| 2020-12-31 | 13.73% | CN¥240.63 Million ≈ $35.21 Million |
CN¥1.75 Billion ≈ $256.41 Million |
-- |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildi… Read more